nivolumab,ipilimumab,cabozantinib
bms
['nivolumab', 'rcc,(-irccs),(-srcc),(-urcc)', 'cabozantinib', ' ipi ', 'cosmic313', '#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)', 'nivo', 'cosmic-313']
outcomes by imdc risk in the #cosmic313 phase 3 trial evaluating cabozantinib + nivo and ipi in first-line advanced #rcc of imdc intermediate or poor risk. presented by . #gu23 written coverage by &gt; 
Largest global online community of #urological medical professionals & patients. #bladdercancer #menshealth #prostatecancer #kidneycancer #Urology